LIVIVO - Search results -

Search results

Result 1 - 10 of total 143

Search options

Article: Is blinatumomab now standard of care consolidation for patients with ALL?

Luger, Selina M

Clinical advances in hematology & oncology : H&O

2023 Volume 21, Issue 6, Page(s) 281–283

MeSH term(s)	Humans ; Standard of Care ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Antibodies, Bispecific/adverse effects ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Antineoplastic Agents/adverse effects
Chemical Substances	blinatumomab (4FR53SIF3A) ; Antibodies, Bispecific ; Antineoplastic Agents
Language	English
Publishing date	2023-08-02
Publishing country	United States
Document type	Interview
ZDB-ID	2271951-9
ISSN	1543-0790
ISSN	1543-0790
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6505: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark.

Luger, Selina M

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2021 Volume 39, Issue 8, Page(s) 870–875

Abstract: The Oncology Grand Rounds series is designed to place original reports published in ... ...

Abstract	The Oncology Grand Rounds series is designed to place original reports published in the
MeSH term(s)	Adult ; Benchmarking ; Consolidation Chemotherapy/methods ; Female ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/pathology ; Prognosis ; Young Adult
Language	English
Publishing date	2021-01-07
Publishing country	United States
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.20.03142
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Is the current consolidation regimen for AML evidence-based?

Luger, Selina M

Best practice & research. Clinical haematology

2021 Volume 34, Issue 4, Page(s) 101334

Abstract: Current standard of care for consolidation therapy for AML varies based on age and induction regimen, among other factors. Many trials have sought to determine the optimal dose, number of cycles, and schedule for consolidation with cytarabine. For AML ... ...

Abstract	Current standard of care for consolidation therapy for AML varies based on age and induction regimen, among other factors. Many trials have sought to determine the optimal dose, number of cycles, and schedule for consolidation with cytarabine. For AML patients under age 60, mid-dose cytarabine is as effective as high-dose cytarabine, results after 3 or 4 cycles of cytarabine in consolidation are comparable but are both superior to only one cycle, and giving cytarabine every 12 h on days 1, 2, and 3 appears to have the same benefit but less toxicity than cytarabine given on days 1, 3, and 5. For those over age 60, the best dose of cytarabine is unknown, but post-remission therapy appears to improve survival for some patients who achieve remission after standard induction, depending on induction regimen used and MRD status at time of remission.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cytarabine/therapeutic use ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/drug therapy ; Middle Aged ; Remission Induction
Chemical Substances	Cytarabine (04079A1RDZ)
Language	English
Publishing date	2021-11-03
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2048027-1
ISSN	1532-1924 ; 1521-6926
ISSN (online)	1532-1924
ISSN	1521-6926
DOI	10.1016/j.beha.2021.101334
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 1029: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?

Schwab, Robert D / Luger, Selina M

Current treatment options in oncology

2023 Volume 24, Issue 7, Page(s) 757–769

Abstract: Opinion statement: In patients with chronic myeloid leukemia who require second-line tyrosine kinase inhibitor therapy, many options exist. These treatments include alternate generation tyrosine kinase inhibitors and in some cases consideration of ... ...

Abstract	Opinion statement: In patients with chronic myeloid leukemia who require second-line tyrosine kinase inhibitor therapy, many options exist. These treatments include alternate generation tyrosine kinase inhibitors and in some cases consideration of allogeneic transplant. Although efficacious, each tyrosine kinase inhibitor possesses distinct side effects and pharmacological profiles that prevent a generalizable treatment approach. Furthermore, there is limited head-to-head trial data that would suggest the superiority of one tyrosine kinase inhibitor over another to help guide treatment decisions in specific clinical settings. Therefore, we treat each patient independently. A patient's treatment plan must be personalized by a variety of clinical factors to optimize response and tolerability. Our general approach is to first examine the reason for treatment failure, which may be due to either intolerance or relapse. Second, we consider the age and patient's comorbidities such as lung disease, diabetes, or cardiovascular disease. In patients who have inadequate responses, we analyze the patient's BCR-ABL1 mutational profile, which is beneficial if that patient harbors a specific tyrosine kinase inhibitor responsive mutation, such as T315I. Using these steps, we can provide a generalizable approach to choosing the appropriate second-line tyrosine inhibitor for chronic myeloid leukemia.
MeSH term(s)	Humans ; Tyrosine Kinase Inhibitors ; Fusion Proteins, bcr-abl/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Protein Kinase Inhibitors/adverse effects ; Mutation ; Drug Resistance, Neoplasm ; Antineoplastic Agents/therapeutic use
Chemical Substances	Tyrosine Kinase Inhibitors ; Fusion Proteins, bcr-abl (EC 2.7.10.2) ; Protein Kinase Inhibitors ; Antineoplastic Agents
Language	English
Publishing date	2023-04-29
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057351-0
ISSN	1534-6277 ; 1527-2729
ISSN (online)	1534-6277
ISSN	1527-2729
DOI	10.1007/s11864-023-01088-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5523: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Acute myeloid leukemia: How to treat the fit patient over age 75?

Luger, Selina M

Best practice & research. Clinical haematology

2019 Volume 32, Issue 4, Page(s) 101105

Abstract: Survival rates for patients with acute myeloid leukemia (AML) older than 75 years are still quite dismal. Recent approvals, therefore, of two agents specifically to treat older patients-glasdegib and venetoclax-have created excitement among the medical ... ...

Abstract	Survival rates for patients with acute myeloid leukemia (AML) older than 75 years are still quite dismal. Recent approvals, therefore, of two agents specifically to treat older patients-glasdegib and venetoclax-have created excitement among the medical community. Clinical data, particularly complete response (CR) rates and CR with incomplete hematologic recovery (CRi), look quite promising and are reviewed here. Yet the question remains whether fit elderly patients should receive combination therapy containing the newer agents, particularly since intensive chemotherapy remains the only treatment that has demonstrated the ability to achieve long-term disease-free survival.
MeSH term(s)	Aged ; Aged, 80 and over ; Benzimidazoles/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/therapy ; Male ; Phenylurea Compounds/therapeutic use ; Sulfonamides/therapeutic use ; Survival Rate
Chemical Substances	Benzimidazoles ; Bridged Bicyclo Compounds, Heterocyclic ; Phenylurea Compounds ; Sulfonamides ; glasdegib (K673DMO5H9) ; venetoclax (N54AIC43PW)
Language	English
Publishing date	2019-10-19
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2048027-1
ISSN	1532-1924 ; 1521-6926
ISSN (online)	1532-1924
ISSN	1521-6926
DOI	10.1016/j.beha.2019.101105
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 1029: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: How can one optimize induction therapy in AML?

Luger, Selina M

Best practice & research. Clinical haematology

2017 Volume 30, Issue 4, Page(s) 301–305

Abstract: Induction therapy for acute myeloid leukemia has not changed much since 1973, when the 7 + 3 regimen of cytarabine and daunorubicin was born. Since then, various strategies have been evaluated to improve patient response, including dose intensification, ... ...

Abstract	Induction therapy for acute myeloid leukemia has not changed much since 1973, when the 7 + 3 regimen of cytarabine and daunorubicin was born. Since then, various strategies have been evaluated to improve patient response, including dose intensification, the incorporation of additional agents into the regimen, the development of novel agents, and modified approaches for older patients. Recently, two novel agents, CPX-351 and gemtuzumab ozogamicin, have been approved by the US Food and Drug Administration. This review discusses each of the induction strategies and their impact on patient outcomes.
MeSH term(s)	Aminoglycosides/history ; Aminoglycosides/therapeutic use ; Antibodies, Monoclonal, Humanized/history ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cytarabine/history ; Cytarabine/therapeutic use ; Daunorubicin/history ; Daunorubicin/therapeutic use ; History, 20th Century ; History, 21st Century ; Humans ; Induction Chemotherapy/history ; Induction Chemotherapy/methods ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/history
Chemical Substances	Aminoglycosides ; Antibodies, Monoclonal, Humanized ; Cytarabine (04079A1RDZ) ; gemtuzumab (93NS566KF7) ; Daunorubicin (ZS7284E0ZP)
Language	English
Publishing date	2017-10-04
Publishing country	Netherlands
Document type	Historical Article ; Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2048027-1
ISSN	1532-1924 ; 1521-6926
ISSN (online)	1532-1924
ISSN	1521-6926
DOI	10.1016/j.beha.2017.10.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 1029: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?

McCurdy, Shannon R / Luger, Selina M

Haematologica

2021 Volume 106, Issue 10, Page(s) 2544–2554

Abstract: Intensive chemotherapy has been the backbone of the treatment of acute myeloid leukemia (AML) for decades. However, an increase in novel targeted agents, which has been brought about in part by a deeper understanding of the genetic makeup of AML, has led ...

Abstract	Intensive chemotherapy has been the backbone of the treatment of acute myeloid leukemia (AML) for decades. However, an increase in novel targeted agents, which has been brought about in part by a deeper understanding of the genetic makeup of AML, has led to remission-inducing regimens that do not require traditional cytotoxic agents. Combinations of a hypomethylating agent (HMA) and venetoclax have doubled the chance of remission for patients considered unfit for induction chemotherapy who would have traditionally been offered singleagent HMA. In fact, this regimen may rival the complete remission rate achieved with induction chemotherapy for certain populations such as the very elderly and those with secondary AML, but equivalency has yet to be established. Further advances include the addition of gemtuzumab ozogamicin and FLT3 inhibitors to induction chemotherapy, which improves survival for patients with core-binding factor and FLT3-mutated AML, respectively. Still, much work is needed to improve the outcomes of the highest-risk subgroups: frail patients and those with high-risk cytogenetics and/or TP53 mutations. Promisingly, the landscape of AML therapy is shifting dramatically and no longer is intensity, when feasible, always the best answer for AML.
MeSH term(s)	Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Gemtuzumab/administration & dosage ; Gemtuzumab/therapeutic use ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Remission Induction
Chemical Substances	Antineoplastic Agents ; Gemtuzumab (93NS566KF7)
Language	English
Publishing date	2021-10-01
Publishing country	Italy
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2020.269134
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Minimal Residual Disease in Acute Myeloid Leukemia.

Sung, Pamela J / Luger, Selina M

Current treatment options in oncology

2017 Volume 18, Issue 1, Page(s) 1

Abstract: Opinion statement: New technology and improved understanding of the pathogenesis of acute leukemias have allowed for sensitive detection of minimal residual disease (MRD). Despite many years of research demonstrating the prognostic value of MRD, there ... ...

Abstract	Opinion statement: New technology and improved understanding of the pathogenesis of acute leukemias have allowed for sensitive detection of minimal residual disease (MRD). Despite many years of research demonstrating the prognostic value of MRD, there is no standard of care for measurement of MRD in acute myeloid leukemia. The techniques for assessment are continuing to improve at a rapid pace; however, the benefit of risk-adapted approaches for MRD positive disease remains a major question. This review focuses on recent methodological advances for MRD detection, the role of MRD in prognostication, and current application of the available evidence in guiding therapy decisions.
MeSH term(s)	Biomarkers, Tumor ; Clinical Decision-Making ; Disease Management ; Flow Cytometry/methods ; Genomics/methods ; Humans ; Immunophenotyping/methods ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/therapy ; Molecular Diagnostic Techniques ; Neoplasm, Residual/diagnosis ; Neoplasm, Residual/pathology
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2017-01
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057351-0
ISSN	1534-6277 ; 1527-2729
ISSN (online)	1534-6277
ISSN	1527-2729
DOI	10.1007/s11864-017-0447-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5523: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation.

Freyer, Craig W / Carulli, Alison / Frey, Noelle V / Gill, Saar I / Hexner, Elizabeth O / Martin, Mary Ellen / Luger, Selina M / Porter, David L / Stadtmauer, Edward A / Loren, Alison W

Leukemia & lymphoma

2024 Volume 65, Issue 2, Page(s) 250–256

Abstract: Calcineurin inhibitor pain syndrome (CIPS) is a rare complication of graft-vs-host disease prophylaxis following allogeneic hematopoietic cell transplant (alloHCT). CIPS presents as severe bilateral lower extremity pain, and the incidence, risk factors, ... ...

Abstract	Calcineurin inhibitor pain syndrome (CIPS) is a rare complication of graft-vs-host disease prophylaxis following allogeneic hematopoietic cell transplant (alloHCT). CIPS presents as severe bilateral lower extremity pain, and the incidence, risk factors, and management of CIPS are poorly characterized.This is a single center retrospective study of patients who received tacrolimus (TAC) following alloHCT to describe the characteristics and management of CIPS and compare to a cohort who did not develop CIPS.Fifteen of 585 alloHCT patients (2.6%) developed CIPS at a median of 5 days following TAC initiation and a median level of 10.5 ng/mL. Severe bilateral foot, ankle, or leg pain were the primary symptoms. Patients with CIPS were younger and more frequently received myeloablative conditioning and total body irradiation compared to patients without CIPS. Analgesic regimens included dihydropyridine calcium channel blockers, gabapentinoids, topical diclofenac, and opioids.Clinicians should be aware of this uncommon but severe adverse effect.
MeSH term(s)	Humans ; Calcineurin Inhibitors ; Hematopoietic Stem Cell Transplantation ; Retrospective Studies ; Tacrolimus ; Diclofenac
Chemical Substances	Calcineurin Inhibitors ; Tacrolimus (WM0HAQ4WNM) ; Diclofenac (144O8QL0L1)
Language	English
Publishing date	2024-01-24
Publishing country	United States
Document type	Journal Article
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.1080/10428194.2023.2281266
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Relapsed T Cell ALL: Current Approaches and New Directions.

McMahon, Christine M / Luger, Selina M

Current hematologic malignancy reports

2019 Volume 14, Issue 2, Page(s) 83–93

Abstract: Purpose of review: Patients with relapsed T cell acute lymphoblastic leukemia (T-ALL) have limited therapeutic options and a poor prognosis. Although a variety of salvage chemotherapy regimens may be used, response rates are unsatisfactory. This article ...

Abstract	Purpose of review: Patients with relapsed T cell acute lymphoblastic leukemia (T-ALL) have limited therapeutic options and a poor prognosis. Although a variety of salvage chemotherapy regimens may be used, response rates are unsatisfactory. This article summarizes current approaches and promising emerging strategies for the treatment of relapsed T-ALL. Recent findings: Although nelarabine is the only agent approved specifically for T-ALL, recent studies have identified a variety of genetic alterations and signaling pathways that are critical in its pathogenesis. Based on these findings, a number of small-molecule inhibitors and other targeted therapies are being studied for relapsed T-ALL, including gamma-secretase inhibitors, BCL-2 inhibitors, cyclin-dependent kinase inhibitors, and mTOR inhibitors. In addition, pre-clinical studies of chimeric antigen receptor T cells targeting CD5 and CD7 as well as the monoclonal antibody daratumumab have shown promising results for T-ALL. Relapsed T-ALL currently remains challenging to treat, but recent pre-clinical studies of targeted and immunotherapeutic agents have shown encouraging results. A number of clinical trials investigating these approaches for T-ALL are currently underway.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Arabinonucleosides/therapeutic use ; Drug Resistance, Neoplasm/drug effects ; Humans ; Liposomes/chemistry ; Neoplasm Recurrence, Local ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Salvage Therapy/methods ; Vincristine/chemistry ; Vincristine/therapeutic use
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents ; Arabinonucleosides ; Liposomes ; daratumumab (4Z63YK6E0E) ; Vincristine (5J49Q6B70F) ; nelarabine (60158CV180)
Language	English
Publishing date	2019-04-16
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	2229765-0
ISSN	1558-822X ; 1558-8211
ISSN (online)	1558-822X
ISSN	1558-8211
DOI	10.1007/s11899-019-00501-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6332: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito